Company intelligence / Profile preview
Sionna Therapeutics, Inc.
Waltham, Massachusetts, United Statessionnatx.com ↗
- Ownership
- Public · SION
- Employees
- ~41
- Development stage
- Phase 1
01
Overview
Sionna Therapeutics is advancing multiple clinical programs targeting NBD1 stabilization and complementary CFTR modulators for cystic fibrosis treatment. The company has completed Phase 2 trials for galicaftor (SION-2222) and navocaftor (SION-3067), and has several compounds in Phase 1 trials including SION-109, SION-719, and SION-451.
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
AbbVie
04
Financials
- Market cap
- $344M
- Total revenue
- $0
- Enterprise value
- $141.1M
Beyond the preview
Go deeper on Sionna Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sionna Therapeutics, Inc..